CoChat

Fertility and reproductive outcome after tubal ectopic pregnancy: comparison among methotrexate, surgery and expectant management

Open access
Baggio, Silvia, Garzon, Simone, Russo, Anna, Ianniciello, Cesare Quintino, Santi, Lorenza, Laganà, Antonio Simone, Raffaelli, Ricciarda, Franchi, Massimo · 2021 · Archives of Gynecology and Obstetrics

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; none of the 7 sources its claims cite is checked for support yet.

Abstract

Purpose: To compare fertility and reproductive outcome after surgical, medical, and expectant management for tubal ectopic pregnancy (EP). Methods: 133 of 228 patients, who were managed between January 2012 and December 2017 for a tubal EP, tried to conceive immediately after treatment: 86 out of 173 (49.7%) underwent surgical treatment; 38 (21.9%) were treated with methotrexate (MTX), and 49 (28.3%) had expectant management. Clinical data were retrieved by medical records, fertility outcomes were obtained by phone follow-up. The cumulative incidence (CI) of intrauterine clinical pregnancy (CP), miscarriage, live birth (LB), and recurrent EP, and the time between treatment and first intrauterine CP were compared between women treated with MTX, surgery and expectant management. Results: The CI of intrauterine CP starting from 12 months after the EP was 65.3% for the expectant management, 55.3% for the MTX group, and 39.5% for surgery (p = 0.012). Post-hoc analysis showed expectant management having higher intrauterine CP and LB, and shorter time between treatment and first intrauterine CP compared to surgery (p < 0.05). The CI of recurrent EP was comparable between the 3 groups. The analysis stratified per βhCG cut-off of 1745 mUI/mL and EP mass cut-off of 25 mm reported consistent results. Conclusions: Women successfully managed by expectation appear to have better reproductive outcomes compared to women who underwent surgery, with the shortest time to achieve a subsequent intrauterine CP. Therefore, if safely applicable the expectant management should be considered in the case of tubal EP. The fact that the chosen treatment was primarily guided by the βhCG value and EP mass diameter based on the protocol, which is intrinsically related to the characteristics of the EP, represents the main limitation of the present study. Indeed, we cannot completely exclude that the observed differences between treatments are related to the EP itself instead of the treatment.

Overview

CoChat Summary

## TL;DR

This retrospective cohort study compared expectant management, methotrexate (MTX), and surgery for tubal ectopic pregnancy and found a progressively better reproductive prognosis from surgery to MTX to expectant management. Expectant management had the highest cumulative incidence of subsequent intrauterine pregnancy and live birth, and the shortest time to the next intrauterine pregnancy when clinical conditions allowed it.

## Key findings

  • Among 173 women who actively tried to conceive after the index tubal ectopic pregnancy, final treatment success was 70% (49/70) for expectant management, 82.6% (38/46) for MTX, and 100% (86/86) for surgery.
  • On intention-to-treat analysis, success was 70% (49/70) for expectant management, 83.3% (30/36) for MTX, and 100% (67/67) for surgery.
  • Expectant management was associated with the highest cumulative incidence of intrauterine clinical pregnancy and live birth and the shortest time to achieve an intrauterine pregnancy; statistically significant differences were reported only versus surgery.
  • Recurrent ectopic pregnancy did not differ significantly among the three approaches; the paper reports recurrence proportions up to 8.5%, with 10% in MTX and 8.1% in surgery.

## Methods

  • Retrospective cohort study at the University Hospital of Verona, identifying women with clinically suspected tubal ectopic pregnancy treated between January 2012 and December 2017.
  • From 228 admitted women, 204 eligible patients remained after exclusions; 173 women who actively tried to conceive and consented to telephone follow-up were included in reproductive outcome analyses.
  • Outcomes were assessed by phone interview 12–80 months after treatment; the main analyses compared cumulative incidence of intrauterine clinical pregnancy, miscarriage, live birth, recurrent ectopic pregnancy, and time to next intrauterine pregnancy across expectant management, MTX, and surgery, with stratified analyses by βhCG 1745 mIU/mL and ectopic mass diameter 25 mm.

## Limitations

  • The paper states that treatment choice was guided by βhCG level and ectopic mass diameter according to protocol, which is “intrinsically related” to the pregnancy characteristics; therefore, the observed differences may reflect the ectopic pregnancy itself rather than the treatment.
  • The study is retrospective and non-randomized, which the authors note limits causal inference and introduces possible confounding.
  • The paper also notes a limited sample size and operator-dependence of ultrasound measurement; additionally, because surgery was the mandated option for larger masses or higher βhCG values, comparisons in those strata are limited (evident from the text).

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1007/s00404-020-05749-2

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Flowchart of study population (EP ectopic pregnancy, LPS laparoscopy, MTX methotrexate)
Fig. 1 Flowchart of study population (EP ectopic pregnancy, LPS laparoscopy, MTX methotrexate)CC BY · PubMed Central

Verification

Claims the paper makes

0 Valid · 0 Not valid · 5 Not checked · 50 Own results and interpretations

22 more claims

Create a free account to see all 55 claims and to verify the 7 references still open.

See all claims — free account
  • It may state two separate claims as one. 21
  • Probably not a substantial claim. 10
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 32 references

Cited by

See all 78

Metadata

Authors
Baggio, S., Garzon, S., Russo, A., Ianniciello, C. Q., Santi, L., Laganà, A. S., Raffaelli, R., & Franchi, M.
Affiliations
  • University of Verona (IT)
  • University of Insubria (IT)
Corresponding author
Baggio, Silvia
Venue
Archives of Gynecology and Obstetrics
Published
2020-08-27
Volume
303
Issue
1
Pages
259-268
ISSN
  • 0003-9128 (ISSN-L)
  • 0932-0067
  • 1432-0711
OpenAlex
W3081304713
Cited by
56
References
32
Citations by year
2026: 5 · 2025: 12 · 2024: 12 · 2023: 12 · 2022: 10 · 2021: 5
FWCI
5.05
Type
journal article
Language
en
Open access
Licence
Locations
  • Archives of Gynecology and Obstetrics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Università degli Studi di Verona
Topics
  • Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Reproductive Health and Contraception
  • Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
Keywords
tubal pregnancy, fertility outcomes, expectant management, methotrexate, surgical management, recurrent ectopic pregnancy, clinical pregnancy, live birth, miscarriage, beta-hCG
MeSH terms
Adult, Female, Fertility, Humans, Methotrexate, Pregnancy, Pregnancy, Tubal, Reproduction, Salpingostomy, Treatment Outcome, Watchful Waiting, Salpingectomy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fertility and reproductive outcome after tubal ectopic pregnancy: comparison among methotrexate, surgery and expectant management. https://app.cochat.ai/papers/10.1007/s00404-020-05749-2
The paper
Baggio, S., Garzon, S., Russo, A., Ianniciello, C. Q., Santi, L., Laganà, A. S., Raffaelli, R., & Franchi, M. (2021). Fertility and reproductive outcome after tubal ectopic pregnancy: comparison among methotrexate, surgery and expectant management. Archives of Gynecology and Obstetrics. https://doi.org/10.1007/s00404-020-05749-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.